Deep learning enables rapid identification of potent DDR1 kinase inhibitors.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
09 2019
Historique:
received: 01 11 2018
accepted: 12 07 2019
pubmed: 4 9 2019
medline: 7 11 2019
entrez: 4 9 2019
Statut: ppublish

Résumé

We have developed a deep generative model, generative tensorial reinforcement learning (GENTRL), for de novo small-molecule design. GENTRL optimizes synthetic feasibility, novelty, and biological activity. We used GENTRL to discover potent inhibitors of discoidin domain receptor 1 (DDR1), a kinase target implicated in fibrosis and other diseases, in 21 days. Four compounds were active in biochemical assays, and two were validated in cell-based assays. One lead candidate was tested and demonstrated favorable pharmacokinetics in mice.

Identifiants

pubmed: 31477924
doi: 10.1038/s41587-019-0224-x
pii: 10.1038/s41587-019-0224-x
doi:

Substances chimiques

Enzyme Inhibitors 0
Discoidin Domain Receptor 1 EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1038-1040

Commentaires et corrections

Type : CommentIn

Références

Paul, S. M. et al. Nat. Rev. Drug Discov. 9, 203–214 (2010).
doi: 10.1038/nrd3078
Avorn, J. N. Engl. J. Med. 372, 1877–1879 (2015).
doi: 10.1056/NEJMp1500848
Goodfellow, I. et al. Generative adversarial nets. in Advances in Neural Information Processing Systems 2672–2680 (2014).
Mamoshina, P. et al. Mol. Pharm. 13, 1445–1454 (2016).
doi: 10.1021/acs.molpharmaceut.5b00982
Sanchez-Lengeling, B. & Aspuru-Guzik, A. Science 361, 360–365 (2018).
doi: 10.1126/science.aat2663
Kadurin, A. et al. Oncotarget 8, 10883–10890 (2016).
pmcid: 5355231
Kadurin, A. et al. Mol. Pharm. 14, 3098–3104 (2017).
doi: 10.1021/acs.molpharmaceut.7b00346
Gómez-Bombarelli, R. et al. ACS Cent. Sci. 4, 268–276 (2018).
doi: 10.1021/acscentsci.7b00572
Putin, E. et al. Mol. Pharm. 15, 4386–4397 (2018).
doi: 10.1021/acs.molpharmaceut.7b01137
Putin, E. et al. J. Chem. Inf. Model. 58, 1194–1204 (2018).
doi: 10.1021/acs.jcim.7b00690
Harel, S. & Radinsky, K. Mol. Pharm. 15, 4406–4416 (2018).
doi: 10.1021/acs.molpharmaceut.8b00474
Polykovskiy, D. et al. Mol. Pharm. 15, 4398–4405 (2018).
doi: 10.1021/acs.molpharmaceut.8b00839
Kuzminykh, D. et al. Mol. Pharm. 15, 4378–4385 (2018).
doi: 10.1021/acs.molpharmaceut.7b01134
Segler, M. H. S. et al. Nature 555, 604–610 (2018).
doi: 10.1038/nature25978
Merk, D. et al. Mol. Inform. 37, 1–2 (2018).
doi: 10.1002/minf.201700153
Merk, D. et al. Commun. Chem. 1.1, 68 (2018).
doi: 10.1038/s42004-018-0068-1
Moll, S. et al. Biochim. Biophys. Acta Mol. Cell Res. https://doi.org/10.1016/j.bbamcr.2019.04.004 (2019).
doi: 10.1016/j.bbamcr.2019.04.004
Richter, H. et al. ACS Chem. Biol. 14, 37–49 (2019).
doi: 10.1021/acschembio.8b00866
Elton, D. C. et al. Mol. Syst. Des. Eng. 4, 828–849 (2019).
doi: 10.1039/C9ME00039A
Irwin, J. J. et al. J. Chem. Inf. Model. 52, 1757–1768 (2012).
doi: 10.1021/ci3001277
Oseledets, I. V. SIAM J. Sci. Comput. 33, 2295–2317 (2011).
doi: 10.1137/090752286
Williams, R. J. Mach. Learn. 8, 229–256 (1992).
Brown, N. et al. J. Chem. Inf. Model. 59, 1096–1108 (2018).
doi: 10.1021/acs.jcim.8b00839
Guimaraes, G. L. et al. Objective-Reinforced Generative Adversarial Networks (ORGAN) for sequence generation models. Preprint at https://arxiv.org/abs/1705.10843 (2017).
Sanchez-Lengeling, B. et al. Optimizing distributions over molecular space. An Objective-Reinforced Generative Adversarial Network for Inverse-design Chemistry (ORGANIC). Preprint at https://chemrxiv.org/articles/ORGANIC_1_pdf/5309668 (2017).
Ritter, H. & Kohonen, T. Biol. Cybern. 61, 241–254 (1989).
doi: 10.1007/BF00203171
Sammon, J. W. IEEE Trans. Comput. C-18, 401–409 (1969).
doi: 10.1109/T-C.1969.222678
Rappe, A. K. J. Am. Chem. Soc. 114, 10024–10035 (1992).
doi: 10.1021/ja00051a040

Auteurs

Alex Zhavoronkov (A)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong. alex@insilico.com.

Yan A Ivanenkov (YA)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Alex Aliper (A)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Mark S Veselov (MS)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Vladimir A Aladinskiy (VA)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Anastasiya V Aladinskaya (AV)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Victor A Terentiev (VA)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Daniil A Polykovskiy (DA)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Maksim D Kuznetsov (MD)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Arip Asadulaev (A)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Yury Volkov (Y)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Artem Zholus (A)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Rim R Shayakhmetov (RR)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Alexander Zhebrak (A)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Lidiya I Minaeva (LI)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Bogdan A Zagribelnyy (BA)

Insilico Medicine Hong Kong Ltd, Pak Shek Kok, New Territories, Hong Kong.

Lennart H Lee (LH)

WuXi AppTec Co., Ltd, Shanghai, China.

Richard Soll (R)

WuXi AppTec Co., Ltd, Shanghai, China.

David Madge (D)

WuXi AppTec Co., Ltd, Shanghai, China.

Li Xing (L)

WuXi AppTec Co., Ltd, Shanghai, China.

Tao Guo (T)

WuXi AppTec Co., Ltd, Shanghai, China.

Alán Aspuru-Guzik (A)

Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
Vector Institute for Artificial Intelligence, Toronto, Ontario, Canada.
Canadian Institute for Advanced Research, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH